Suppr超能文献

治疗性雄激素受体配体

Therapeutic androgen receptor ligands.

作者信息

Allan George F, Sui Zhihua

机构信息

Johnson and Johnson Pharmaceutical Research and Development, Department of Reproductive Therapeutics, Raritan, NJ 08869, USA.

出版信息

Nucl Recept Signal. 2003;1:e009. doi: 10.1621/nrs.01009. Epub 2003 Sep 27.

Abstract

In the past several years, the concept of tissue-selective nuclear receptor ligands has emerged. This concept has come to fruition with estrogens, with the successful marketing of drugs such as raloxifene. The discovery of raloxifene and other selective estrogen receptor modulators (SERMs) has raised the possibility of generating selective compounds for other pathways, including androgens (that is, selective androgen receptor modulators, or SARMs).

摘要

在过去几年中,组织选择性核受体配体的概念应运而生。随着雷洛昔芬等药物的成功上市,这一概念在雌激素领域得以实现。雷洛昔芬及其他选择性雌激素受体调节剂(SERM)的发现,增加了开发针对其他信号通路(包括雄激素,即选择性雄激素受体调节剂,或SARM)的选择性化合物的可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6818/1402218/d872ea2b7199/nrs01009.f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验